All News

Rituximab-pvvr (Ruxience, Pfizer) is approved to treat non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Rituximab-pvvr (Ruxience, Pfizer) is approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Researchers achieve first success in linking a solid tumor with blood biomarkers, which is often an indicator of whether a patient with breast cancer will remain in remission.

If approved, pembrolizumab in combination with lenvatinib will be indicated for the first-line treatment of advanced unresectable hepatocellular carcinoma.

Pharmacists play an important role as part of the health care team.

Individuals with persistent HIV in the cells of their cerebrospinal fluid are more likely to experience neurocognitive impairment.

Top news of the day from across the health care landscape.

The drug is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus. It is only intended to use in acute care settings under medical supervision.

Scientific advances could lead to earlier prevention and treatment of infection, helping to avoid irreversible or severe chronic diseases.

Why does this woman have excessive facial and neck movements?

Top news of the day from across the health care landscape.

InvaGen’s Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg are therapeutically equivalent to Pfizer's pregabalin capsules (Lyrica).

Seizures triggered by tramadol have been observed with higher and lower doses, and co-ingestion of alcohol, tricyclic antidepressants, antipsychotics, and selective serotonin reuptake inhibitors.

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The first oncology therapeutic biosimilars are now available in the United States.

A binational team of investigators at the University of California, Davis, has conducted the first comprehensive study to examine the risk factors for Rocky Mountain spotted fever in Mexicali, Mexico. They found that citywide, just 1 in 1000 ticks was infected with the disease, but in certain neighborhoods, about 1 in 10 ticks was infected.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than 661,000 Americans have kidney failure.

Individuals with HIV maintained similar rates of viral suppression after switching from a 3-drug regimen to the 2-drug regimen of dolutegravir plus lamivudine.

Photobiomodulation therapy found effective for the prevention of oral mucositis caused by radiation therapy.

Top news of the day from across the health care landscape.